Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 13
2018 18
2019 23
2020 16
2021 20
2022 10
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Cited In for PMID: 28139405

112 results

Results by year

Filters applied: . Clear all
Page 1
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Zelenetz AD, et al. Lancet Oncol. 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28. Lancet Oncol. 2017. PMID: 28139405 Free PMC article. Clinical Trial.
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, Wang X, Liu Z, Yang C, Zheng Y, Li X, Lu Y, To KKW, Xia C, Zhang J, Shi Z, Hu Z, Huang M, Fu L. Wang F, et al. Acta Pharm Sin B. 2024 Mar;14(3):905-952. doi: 10.1016/j.apsb.2023.12.010. Epub 2023 Dec 16. Acta Pharm Sin B. 2024. PMID: 38486980 Free PMC article. Review.
Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH, Wu YY, Huang TC, Lin C, Zou YF, Cheng JC, Chen PH, Jhou HJ, Ho CL. Lee CH, et al. Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD013474. doi: 10.1002/14651858.CD013474.pub2. Cochrane Database Syst Rev. 2024. PMID: 38174814 Review.
Development and Clinical Applications of PI3K/AKT/mTOR Pathway Inhibitors as a Therapeutic Option for Leukemias.
DA Costa Machado AK, Machado CB, DE Pinho Pessoa FMC, Barreto IV, Gadelha RB, DE Sousa Oliveira D, Ribeiro RM, Lopes GS, DE Moraesfilho MO, DE Moraes MEA, Khayat AS, Moreira-Nunes CA. DA Costa Machado AK, et al. Cancer Diagn Progn. 2024 Jan 3;4(1):9-24. doi: 10.21873/cdp.10279. eCollection 2024 Jan-Feb. Cancer Diagn Progn. 2024. PMID: 38173664 Free PMC article. Review.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani A, Winter A, Winter J, Gordan L, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. Hill BT, et al. Blood Adv. 2024 Jan 23;8(2):378-387. doi: 10.1182/bloodadvances.2023010693. Blood Adv. 2024. PMID: 37871300 Free PMC article.
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Glaviano A, et al. Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6. Mol Cancer. 2023. PMID: 37596643 Free PMC article. Review.
Infections in patients with chronic lymphocytic leukemia.
Guarana M, Nucci M. Guarana M, et al. Hematol Transfus Cell Ther. 2023 Jul-Sep;45(3):387-393. doi: 10.1016/j.htct.2023.05.006. Epub 2023 Jul 1. Hematol Transfus Cell Ther. 2023. PMID: 37407362 Free PMC article. Review.
112 results